“The second quarter of 2025 has been very productive, with milestones from each of our clinical programs,” stated Lisa Ricciardi, Cognition’s president and CEO. “These accomplishments highlight the potential for zervimesine to slow the progression of age-related degenerative diseases such as Alzheimer’s disease, dementia with Lewy bodies and dry age-related macular degeneration. The clinical findings from each program have been supplemented by the publication of proteomic analyses and in vitro studies that support the mechanism of action of zervimesine in these patient populations.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGTX:
- Cognition Therapeutics’ Expanded Access Program for CT1812: A Promising Update for Investors
- Cognition Therapeutics presents data at AAIC on CT1812 in dementia
- Cognition Therapeutics publishes results of analysis from Phase 2 SEQUEL study
- Cognition Therapeutics ot present data from zervimesine Phase 2 study
- Cognition Therapeutics Receives Buy Rating Amid Promising Developments and Regulatory Advancements for Zervimesine